All In Biotech

Drug Trial Radar · NCT07453004

A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With Acute Gouty Arthritis

A Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Phase II Clinical Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Punarlimab in Subjects With Acute Gouty Arthritis

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 170 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

170

Planned (sponsor's estimate)

Start

Mar 26, 2026

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
TJ Biopharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Mar 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi center,randomized,double-blind,double-dummy,active-controlled study,and planned enrollment of 120-170 subjects,an interim analysis will be conducted after first 60 subjects complete the 72 -hour pain Visual Analogue Scale(VAS) assessment following their initial dose.Based on the analysis result,the sample size may be adjusted, and 1or 2 group(s)of the investigational drug will be selected to continue enrollment along with the active comparator group.The goal is to evaluate the efficacy of plonmarlimab in subjects with acute gouty arthristis.

Conditions

  • Acute Gouty Arthritis

Interventions

  • PlonmarlimabDrug

    single dose, intravenous infusion

  • Compound betamethasoneDrug

    single dose, intramuscular injection

  • Plonmarlimab placeboDrug

    single dose, intravenous infusion

  • Compound betamethasone placeboDrug

    single dose, intramuscular injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Visual Analogue Scale(VAS) scoreTime frame: 72 hours after the initial dose.

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical University

    Bengbu, Anhui, China · Not yet recruiting

  • The Second Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • Jiangmen Central Hospital

    Jiangmen, Guangdong, China · Not yet recruiting

  • Zhongshan Hospital of Traditional Chinese Medicine

    Zhongshan, Guangdong, China · Not yet recruiting

  • The first affiliated Hospital of Guilin Medical University

    Guilin, Guangxi, China · Not yet recruiting

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China · Not yet recruiting

  • The Second Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China · Not yet recruiting

  • Hebei Petro China Central Hospital

    Langfang, Hebei, China · Not yet recruiting

  • The First Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Not yet recruiting

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China · Not yet recruiting

  • Zhengzhou Central Hospital

    Zhengzhou, Henan, China · Not yet recruiting

  • UnHospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Not yet recruiting

  • The central Hospital of Xiangtan

    Xiangtan, Hunan, China · Not yet recruiting

  • Zhuzhou Central Hospital

    Zhuzhou, Hunan, China · Not yet recruiting

  • Wuxi People's Hospital

    Wuxi, Jiangsu, China · Not yet recruiting

  • Northern Jiangsu People's Hospital

    Yangzhou, Jiangsu, China · Not yet recruiting

  • First Affiliated Hospital of Gannan Medical University

    Ganzhou, Jiangxi, China · Not yet recruiting

  • PingXiang People's Hospital

    Pingxiang, Jiangxi, China · Not yet recruiting

  • The People's Hospital of Jilin Province

    Changchun, Jilin, China · Not yet recruiting

  • Shandong Medical and Pharmaceutical University Hospital

    Binzhou, Shandong, China · Not yet recruiting

  • Jining NO.1 People's Hospital

    Jining, Shandong, China · Not yet recruiting

  • Linyi People Hospital

    Linyi, Shandong, China · Not yet recruiting

  • Zaozhuang Municipal Hospital

    Zaozhuang, Shandong, China · Not yet recruiting

  • Renji Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China · Recruiting

  • Linfen Central Hospital

    Linfen, Shanxi, China · Not yet recruiting

  • Shanxi Bethune Hospital

    Taiyuan, Shanxi, China · Not yet recruiting

  • Chengdu fifth People's Hospital

    Chengdu, Sichuan, China · Not yet recruiting

  • Mianyang Central Hospital

    Mianyang, Sichuan, China · Not yet recruiting

  • The first People's Hospital of Yibin

    Yibin, Sichuan, China · Not yet recruiting

  • Huzhou Third People's Hospital

    Huzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.